Agilent Technologies Inc (NYSE:A) reached a new 52-week high on Tuesday . The stock traded as high as $75.11 and last traded at $73.94, with a volume of 1843921 shares. The stock had previously closed at $74.67.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. ValuEngine raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, September 13th. Morgan Stanley boosted their target price on shares of Agilent Technologies from $83.00 to $84.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 15th. Deutsche Bank boosted their target price on shares of Agilent Technologies from $77.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, August 15th. Finally, Cleveland Research downgraded shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a research report on Monday, November 12th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Agilent Technologies presently has an average rating of “Buy” and a consensus target price of $78.75.
The company has a current ratio of 3.29, a quick ratio of 2.74 and a debt-to-equity ratio of 0.39. The firm has a market cap of $23.06 billion, a P/E ratio of 26.13, a PEG ratio of 2.02 and a beta of 1.36.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 23rd. Stockholders of record on Monday, December 31st will be issued a $0.164 dividend. The ex-dividend date is Friday, December 28th. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 annualized dividend and a dividend yield of 0.90%. Agilent Technologies’s payout ratio is 21.51%.
Agilent Technologies declared that its board has approved a stock buyback plan on Monday, November 19th that allows the company to repurchase $1.75 billion in shares. This repurchase authorization allows the medical research company to repurchase up to 8.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board believes its stock is undervalued.
In other news, VP Rodney Gonsalves sold 1,500 shares of Agilent Technologies stock in a transaction dated Wednesday, November 28th. The shares were sold at an average price of $71.06, for a total value of $106,590.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Heidi Fields sold 5,482 shares of Agilent Technologies stock in a transaction dated Tuesday, September 11th. The shares were sold at an average price of $67.73, for a total transaction of $371,295.86. The disclosure for this sale can be found here. Insiders sold a total of 9,858 shares of company stock valued at $675,179 over the last ninety days.
Several hedge funds and other institutional investors have recently bought and sold shares of A. Vanguard Group Inc. boosted its stake in Agilent Technologies by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 24,155,483 shares of the medical research company’s stock valued at $1,703,929,000 after purchasing an additional 194,607 shares during the period. Morgan Stanley boosted its stake in Agilent Technologies by 6.0% during the 3rd quarter. Morgan Stanley now owns 1,301,103 shares of the medical research company’s stock valued at $91,781,000 after purchasing an additional 73,476 shares during the period. Legal & General Group Plc boosted its stake in Agilent Technologies by 8.8% during the 3rd quarter. Legal & General Group Plc now owns 1,712,847 shares of the medical research company’s stock valued at $120,832,000 after purchasing an additional 138,944 shares during the period. Lombard Odier Asset Management USA Corp acquired a new position in Agilent Technologies during the 3rd quarter valued at about $2,822,000. Finally, Standard Life Aberdeen plc boosted its stake in Agilent Technologies by 13.2% during the 3rd quarter. Standard Life Aberdeen plc now owns 85,030 shares of the medical research company’s stock valued at $5,998,000 after purchasing an additional 9,889 shares during the period.
COPYRIGHT VIOLATION WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/12/04/agilent-technologies-a-hits-new-12-month-high-at-75-11.html.
About Agilent Technologies (NYSE:A)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Read More: Understanding Analyst Ratings
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.